At the World Health Assembly in Geneva, Germany and France signed a joint declaration aimed at strengthening the pharmaceutical industry across Europe. According to the Federal Ministry of Health, the agreement seeks to bolster Germany’s position and ensure long-term access to high-quality, innovative healthcare services.
To support this commitment, a ministerial working group comprised of German and French officials will ensure continuous bilateral exchange and collaboration.
Federal Health Minister Nina Warken (CDU) stated that the declaration significantly deepens the bilateral relationship between the two countries in a crucial area of both supply and economics. She emphasized that Europe must reinforce its status as a center for pharmaceutical research, development, and production, positioning Germany and France to stand together when facing global challenges. The goal, she noted, is to improve the framework for a resilient and sustainable drug landscape.
The concrete objectives outlined in the declaration include accelerating and harmonizing clinical trials, simplifying the introduction of new therapies through mandatory European benefit assessments, providing incentives for production within the EU, and securing a careful balance between environmental regulations and local economic interests, alongside strengthening intellectual property protection.
In partnership with France, the Ministry confirmed that both nations will support long-term structural reforms at the EU level. These measures are designed to restore and sustain the attractiveness and resilience of the entire medicines landscape.